Catalytically active human flavin-containing monooxygenase isoform 2 (FMO2.1) is encoded by an allele detected only in individuals of African or Hispanic origin. Genotyping and haplotyping studies indicate that S195L and N413K occasionally occur secondary to the functional FMO2*1 allele encoding reference protein Gln472. Sulfoxygenation under a range of conditions reveals the role these alterations may play in individuals expressing active FMO2 and provides insight into FMO structure. Expressed S195L lost rather than gained activity as pH was increased or when cholate was present. The activity of S195L was mostly eliminated after heating at 45°C for 5 min in the absence of NADPH, but activity was preserved if NADPH was present. By contrast, Gln472 was less sensitive to heat, a response not affected by NADPH. A major consequence of the S195L mutation was a mean 12-fold increase in K m for NADPH compared with Gln472. Modeling an S213L substitution, the equivalent site, in the structural model of FMO from the Methylophaga bacterium leads to disruption of interactions with NADP ؉ . N413K had the same pattern of activity as Gln472 in response to pH, cholate, and magnesium, but product formation was always elevated by comparison. N413K also lost more activity when heated than Gln472; however, NADPH attenuated this loss. The major effects of N413K were increases in velocity and k cat compared with Gln472. Although these allelic variants are expected to occur infrequently as mutations to the FMO2*1 allele, they contribute to our overall understanding of mammalian FMO structure and function.
Mammalian flavin-containing monooxygenases (FMOs, EC 1.14.13.8) oxygenate many xenobiotics including pharmaceuticals and pesticides that are ingested, inhaled, or otherwise absorbed . Bound FAD is reduced by equivalents from NADPH and subsequently reacts with molecular oxygen-generating C4a-hydroperoxyflavin intermediate; bound NADP ϩ stabilizes the intermediate. In the absence of substrate, oxidized flavin and reduced NADPH are slowly regenerated with concomitant release of hydrogen peroxide. However, when substrate possessing a soft nucleophile (primarily N and S but also Se and P) is present, it is quickly oxygenated by the activated intermediate. Oxygenation generally yields less toxic and more readily excreted metabolites; however, bioactivation can also result. FMOs are a family of related enzymes, each comprising a single isoform. In humans there are five potentially functional FMOs (1-5) and six pseudogenes (Hines et al., 2002; Hernandez et al., 2004) . The amino acid sequence identity of encoded isoforms is 51 to 57%. FMO1, FMO2, and FMO3 are the most extensively studied as they are the primary isoforms catalyzing xenobiotic metabolism.
FMO2 is the major FMO in lung of most mammals. However, a g.23238CϾT nonsense mutation (FMO2*2A) was discovered in humans (Dolphin et al., 1998) . The resulting sequence encodes a nonfunctional protein with the premature Q472X stop codon and loss of 64 residues. Because the mutation was absent in chimpanzee and gorilla, the authors concluded that the variant arose following divergence of humans and chimpanzees. Initial genotyping studies documented occurrence of the FMO2*1 allele encoding Gln472 and full-length active protein exclusively in individuals of either African or Hispanic/Latino descent (Dolphin et al., 1998; Whetstine et al., 2000) . The percentage of Hispanic/Latino individuals carrying the FMO2*1 allele was 2% among Hispanics of Mexican origin and 7% of Hispanics of Puerto Rican origin (Krueger et al., 2004) . In the first large African-American cohort examined, 26% of the individuals possessed FMO2*1 (Whetstine et al., 2000) . A recent study stratified nearly 2000 African study subjects by country and documented large variation in FMO2*1 occurrence with 26 to 50% of sub-Saharan individuals having at least one FMO2*1 allele Veeramah et al., 2008) . Additional missense and nonsense mutations occur, sometimes with high frequency (Whetstine et al., 2000; Furnes et al., 2003; . However, they are generally predicted to occur secondary to the Q472X truncation (Whetstine et al., 2000; .
Individuals possessing the FMO2*1 allele are predicted to exhibit FMO2-dependent xenobiotic metabolism. Overexpressed FMO2.1 efficiently catalyzes oxygenation of a number of xenobiotics, including small thioureas (Henderson et al., 2004b) , the thioether insecticides disulfoton and phorate (PHT) (Henderson et al., 2004a) , and the antituberculosis prodrug ethionamide . Phenylthiourea and ␣-naphthylthiourea (ANTU) form an intermediate sulfenic acid metabolite capable of glutathione oxidation and FMOdependent redox cycling, resulting in glutathione depletion in vitro (Henderson et al., 2004b) . The primary aim of the current study was to further characterize proteins containing the S195L and N413K missense single nucleotide polymorphisms (SNPs). Both variants are common in individuals of African and Hispanic descent (Furnes et al., 2003; , whereas only S195L is commonly identified in European and Asian individuals as assessed in the National Institute of Environmental Health Sciences environmental genome project (http://egp.gs.washington.edu) ( Table 1) . Although haplotype analysis indicates that these mutations are usually secondary to Q472X , one individual from a previous study population (Furnes et al., 2003) was homozygous for Gln472 and had the N413K mutation. Because N413K is usually secondary to the S195L variant, we expect that some individuals will also have the S195L mutation on the same chromosome as the Gln472-encoding allele. Both variants retain some activity in vitro . In light of the new information on the high occurrence rate of the Gln472 allele in sub-Saharan African populations, understanding the properties of these variants should help us predict the potential impact of these alleles on individual response to xenobiotics and therapeutics. Our secondary aim was to acquire information that would contribute to our understanding of FMO structure and function with the additional insight made possible from the recent crystal (Alfieri et al., 2008) , and the related bacterial Baeyer-Villiger monooxygenase (BVMO) and phenylacetone monooxygenase from Thermobifida fusca (PDB ID code 1W4X) (Malito et al., 2004) .
Materials and Methods
Chemicals. ANTU and ethylenethiourea (ETU) were from Lancaster (Pelham, NH). PHT was purchased from Chem Service, Inc. (West Chester, PA). The remaining chemicals for enzyme assays were purchased from SigmaAldrich (St. Louis, MO).
Cloning and Expression of FMO2 Variants. The polymerase chain reaction primers and conditions used to place FMO2 reference cDNA into pENTR (Invitrogen, Carlsbad, CA) and for subsequent creation of S195L and N413K by QuikChange mutagenesis (Stratagene, La Jolla, CA) are documented elsewhere . Proteins were produced in Sf9 insect cells as reported there. Microsomes were prepared by differential centrifugation (Krueger et al., 2002) from insect cells harvested 96 h postinfection and were resuspended in storage buffer (10 mM potassium phosphate, pH 7.4, 20% glycerol, 1 mM EDTA, and 100 mM phenylmethylsulfonyl fluoride). Microsomal protein concentrations were determined using Coomassie Plus assay (Pierce, Rockford, IL). The FAD content was measured by high-performance liquid chromatography (HPLC) (Henderson et al., 2004a) to estimate FMO holoenzyme levels for use in subsequent determinations of activity.
Evaluation of Enzyme Activity. Oxidation of methyl p-tolyl sulfide (MTS) was analyzed by a published method (Rettie et al., 1990) with some modifications . In brief, standard microsomal incubations contained 100 g of expressed protein (75-200 pmol of FMO) in a total reaction volume of 250 l (0.1 M tricine, pH 9.0, 1 mM EDTA, and 1 mM NADPH). After 3-min preincubation on ice, reactions were initiated by adding MTS to 200 M and transferred to a Dubnoff shaking incubator (Precision Scientific, Winchester, VA) at 37°C. Reactions were stopped after 5 min by placing the tubes on ice and adding 75 l of acetonitrile to precipitate proteins. After centrifugation at 10,000g for 30 min at 4°C, supernatants were analyzed by HPLC with a Waters (Milford, MA) 2695 system equipped with a photodiode array detector. Methyl p-tolyl sulfoxide (MTSO) was separated from MTS on a Waters Novapak C 18 (150 ϫ 3.9 mm) column at 40°C with a flow rate of 0.8 ml/min and detection at 237 nm. Mobile phase was 30% acetonitrile for 4 min to 80% acetonitrile in 2 min and returned to 30% acetonitrile at 8 min in 2 min. Racemic MTSO and MTS eluted at 2.7 and 8.7 min, respectively. MTSO formation was calculated by linear regression from standard curves (r 2 ϭ 0.997) of racemic MTSO (0.5-5 nmol) with a detection limit of 50 pmol. The effects of previous mild heat treatment or the presence of additives to the standard reaction mixture on activity were determined by measuring changes in MTSO formation as already described above. Samples were prepared for assessment of heat stability by dilution with storage buffer to 3 mg of protein/ml and were heated (5 min at 45°C) in the absence or presence of NADPH (1 mM); samples were chilled on ice, and reaction mixtures were a The ancestral allele is shown first and is followed by the alternative nucleotide. The nucleotide present in the minor allele is underlined and bolded. Note that for Q472X the minor ЉCЉ allele is the ancestral allele.
b Furnes et al., 2003. c Frequency for occurrence of the allele encoding Gln472 (FMO2*1) was made from 632 Hispanic individuals (primarily of Mexican and Puerto Rican ancestry) (Krueger et al., 2004) . Estimates for the remaining two alleles were from a subset of the first population, 29 individuals with at least one FMO2*1 allele and 124 individuals homozygous for FMO2*2.
d Frequency data from the National Institute of Environmental Health Sciences SNPs database (http://egp.gs.washington.edu).
prepared for assessment of activity. The effects of sodium cholate (0.5%) and magnesium chloride (3 mM) on FMO2 variant performance were assessed by their respective addition to the reaction mixture just before the 3-min preincubation on ice. Three batches of protein and at least two assays per batch for each variant were performed for each condition. A pH of 9.0 was selected for assays because FMO2s typically exhibit enhanced activity at this pH compared with pH 7.5. The activity of protein variants was compared at three pH levels (8.5, 9.0, and 9.5) with MTS, ANTU, and PHT to determine whether all the proteins showed the same response pattern toward different substrates. MTS assays were performed as described above with 200 M MTS and 5-min incubation. Reactions for oxygenation of ANTU and PHT were performed as with MTS oxygenation, but the reaction mixture volume was reduced to 100 l. Reactions were stopped by addition of 50 l of methanol following 10-min incubation. Supernatants were analyzed by HPLC as previously described for ANTU (Henderson et al., 2004b) and PHT (Henderson et al., 2004a) . In those studies, liquid chromatography/mass spectrometry was used to show that the sole metabolites formed from ANTU and PHT are the sulfenic acid and the S-oxide, respectively. However, as authentic standards were not available for these metabolites, metabolite formation is reported here as peak area per picomole of FMO. The substrate concentrations for ANTU and PHT were 200 and 500 M, respectively. Three batches of protein and at least two assays per batch for each variant were performed for each condition.
Kinetic constants were determined for MTS oxygenation and NADPH oxidation. Studies were performed at pH 9.0 to be consistent with earlier estimates made for ETU metabolism . For determination of kinetics of MTS oxygenation, 50 to 70 g (50 -150 pmol of FMO) of expressed microsomal protein was incubated in a 1-ml reaction (0.1 M tricine, 1 mM EDTA, and 1 mM NADPH). After 3-min preincubation on ice, reactions were initiated by adding MTS (0.6 -200 M for FMO2.1 and N413K; 10 -200 M for S195L). Samples were shaken 4.5 min at 37°C and stopped by addition of 2 ml of ethyl acetate. Samples were vortexed 1 min; the ethyl acetate fraction was transferred to a new tube; and the extraction was repeated. Combined ethyl acetate fractions were brought to dryness in a SpeedVac (Thermo Fisher Scientific, Waltham, MA). The reaction products were resuspended in 100 l of mobile phase, and 50 l was analyzed by HPLC as described above. NADPH oxidation was determined in 1 ml of reaction buffer (0.1 M tricine, pH 9.0, 1 mM EDTA) that contained 100 g of protein (75-200 pmol of FMO), 200 M MTS, NADPH (5-1000 M for all the proteins), and an NADPH-regenerating system (2 mM glucose 6-phosphate and 0.25 U of glucose-6-phosphate dehydrogenase). The reaction time was 2 min, followed by termination with 75 l of acetonitrile on ice. MTSO generated was analyzed in 100-l aliquots with the HPLC procedure described above. Two to three batches of protein were used for each protein, with six concentrations of NADPH. Kinetic constants were estimated using nonlinear regression curve fitting with the Michaelis-Menten module of GraphPad Software Inc. (San Diego, CA) Prism 5.0.
Statistical Analysis. Enzyme activity of the variant proteins was compared with FMO2.1. For kinetic studies this comparison was done using simple unpaired t tests given that the replication level was low (n ϭ 2 or 3 batches of each protein). Because of the small sample size, assumptions of the t test (e.g., normal data, equality of variance) were not assessed. Two-way analysis of variance was used to analyze the effects of protein variant and pH with ANTU, PHT, or MTS as substrate, as well as the effects of additives and heat pretreatment. Appropriate post hoc pair-wise comparisons were made using a t test with a Bonferroni adjustment. SigmaStat version 2.03 (Systat Software, Inc., San Jose, CA) was used for these calculations.
FMO Sequence Alignments and Structural Evaluation. FMO sequences were searched for and identified in either nucleotide or protein databases at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/ sites/gquery) or Ensembl genome databases (http://www.ensembl.org/index. html) to prepare alignments to assess conservation of residues under study. Only unambiguous sequences capable of encoding full-length proteins were included. The only exceptions to this inclusion were FMO2 genes that, although complete, appeared to encode prematurely truncated proteins. All the deposited mammalian sequences (isoforms 1-5) and a noninclusive sampling of more distantly related vertebrate FMOs were included. Variant protein sequences were not included in the alignment, except for known FMO2 truncations. A limited number of nonvertebrate eukaryotes were selected to represent a broad spectrum of FMO evolution, but choices were restricted to FMOs known to produce transcribed message and/or protein. Bacterial FMOs were limited to species that have been characterized in vitro. The sampling strategy was done to achieve maximal depth of coverage for mammalian isoforms, as well as a broad shallow sampling of distantly related FMOs for examination of evolutionary conservation at positions homologous to the variants under study. All the sequences evaluated are listed as a supplement to this article (Supplemental Table S1 ). Sequences were prepared in FASTA format and submitted for on-line ClustalW2 analysis from the EBI web server (http://www.ebi.ac.uk/Tools/clustalw2/) using default settings (Larkin et al., 2007) .
The structural location and consequence of S195L and N413K variants were evaluated by swapping human FMO2 residues with the corresponding residues of Methylophaga sp. FMO (PDB code 2VQ7). PyMOL visualization software (The PyMOL Graphics System; DeLano Scientific, Palo Alto, CA) was used for analysis and figure rendering.
Results
Modulators of FMO Activity. Expressed FMO2.1, S195L, and N413K were evaluated in vitro under a number of conditions commonly used to discriminate FMO isoforms; FMO2s are generally heat-stable and show enhanced enzymatic activity with anionic detergents (Williams et al., 1985) . Results are shown in Fig. 1. FMO2 .1, reference protein encoding Gln472, responded with a highly significant ( p Ͻ 0.01) mean 74 and 46% increase in activity with the addition of cholate and MgCl 2 , respectively. After 5 min of heat, FMO2.1 retained 70% activity ( p Ͻ 0.01) in the absence of NADPH and 73% activity ( p Ͻ 0.05) in the presence of NADPH, relative to unheated protein. As addition of NADPH did not enhance activity of FMO2.1, thermal stability was NADPH-independent.
The pattern of response by N413K to the same treatments was generally similar to that of FMO2.1, albeit of differing magnitudes. Compared with N413K activity at pH 9.0, cholate and MgCl 2 pretreatment resulted in significant ( p Ͻ 0.01) increases: 23 and 18%, respectively. Inactivation by heat treatment without NADPH was highly significant ( p Ͻ 0.01), leading to a 46% loss in activity. However, in contrast to FMO2.1, N413K activity was preserved by NADPH and did not show a decrease in activity following heat pretreatment. The amount of MTSO formed by N413K was much higher ( p Ͻ 0.01) than the amount formed by FMO2.1 for every treatment.
S195L showed a unique pattern of response to the treatments. MgCl 2 did not increase activity ( p ϭ 0.35), and most activity, 89%, was lost by cholate treatment ( p Ͻ 0.01), responses in stark contrast to the pattern observed with both FMO2.1 and N413K. Heat treatment of S195L in the absence of NADPH resulted in a 95% loss of activity ( p Ͻ 0.01). However, coincubation with NADPH during heat exposure rescued S195L activity. The only conditions where S195L activity was not significantly less than that of FMO2.1 were when samples were heated in the presence of NADPH.
Activity of FMO2 isoforms typically increases as pH is elevated above physiological levels, achieving maximal activity at approximately pH 9.5 to 10, a pattern first shown for rabbit FMO2 (Williams et al., 1985) . Human FMO2.1 illustrates this pattern of metabolism when methimazole is the substrate (Krueger et al., 2002) . As shown in Fig. 2 , activity of FMO2.1 increased for each of three substrates as pH was elevated, although activity reached a plateau at pH 9.0 when PHT was the substrate. We evaluated S195L and N413K with the same conditions to determine whether they exhibited the same pattern of activity in response to changing pH (Fig. 2) . N413K activity was higher ( p Ͻ 0.01) than FMO2.1 activity at every pH with all the substrates. Although a pattern of increased activity with elevated pH was observed with all the substrates, activity always reached a plateau at pH 8.5 (ANTU) or pH 9.0 (PHT and MTS), indicating that the incremental response to pH by the N413K variant was less than that of FMO2.1.
The behavior of S195L was in distinct contrast to FMO2.1 and N413K. S195L showed maximal activity at pH 8.5, the lowest pH tested. Activity achieved by S195L at pH 8.5 was significantly less than that of FMO2.1 only with ANTU and was significantly ( p Ͻ 0.01) higher than FMO2.1 when PHT was the substrate. As pH was increased, S195L activity decreased significantly ( p Ͻ 0.01) with all the substrates, with each incremental pH increase. S195L was significantly ( p Ͻ 0.01) less active than FMO2.1 at pH 9.0, the pH used for initial screening of activity .
Kinetic Parameters. Kinetic constants were determined for MTS oxygenation ( Table 2 ). The k cat of S195L was almost 3-fold lower ( p Ͻ 0.05) than FMO2.1. Both proteins had high affinity for MTS, and although the K m of S195L was lower, it did not reach the threshold of significance. Because low reaction velocity limited MTSO formation by S195L, we did not run MTS assays at concentrations less than 10 M. Although we are confident that the true K m of S195L is less than 10 M, our estimate may contain some unaccounted for error; nonetheless, it is not likely to be significantly different from FMO2.1. The K m for N413K was very similar to that of S195L but was not significantly different from that of FMO2.1. However, the k cat for MTS oxygenation by N413K was significantly higher ( p Ͻ 0.01) with this variant. Overall catalytic efficiency of N413K was significantly higher ( p Ͻ 0.05) than that of FMO2.1.
Kinetic constants for NADPH use with MTS as substrate were also determined ( Table 2 ). The K m values for NADPH affinity by FMO2.1 and N413K were low (11.5 and 6.8 M, respectively), indicating both have high affinity; calculated affinities were not significantly different. These affinities were slightly higher than those of pig FMO1 (1.0 -6.5 M), the only other mammalian FMO with NADPH affinity data, using a variety of substrates and a range of pH (7.4 -8.5) (Poulsen and Ziegler, 1979; Beaty and Ballou, 1981; Sabourin and Hodgson, 1984) . The k cat of N413K was significantly higher than that of FMO2.1. The specificity constant of N413K was not significantly elevated compared with FMO2.1, primarily because of the high deviation we had among FMO2.1 batches (n ϭ 3). Nonetheless, it is clear that k cat is the improved feature of this variant, which we reported previously using ETU as the test substrate . The k cat of S195L was no different from that of FMO2.1. By contrast, the affinity of S195L for NADPH was significantly compromised as shown by a mean 12-fold elevation of K m ( p Ͻ 0.05) compared with FMO2.1. The elevated K m that we measured with S195L is similar to the 9-fold increase observed with the K219A mutant of Baker's yeast (Suh et al., 1999) , located near the GxGxxG/A NADPH-binding motif (Supplemental Fig. S1 ). The specificity constant of S195L did not differ significantly from that of FMO2.1.
We verified that k cat estimates for individual proteins did not differ significantly under the two sets of assay conditions. In addition, we verified that k cat estimates of 41 and 124 min Ϫ1 previously reported for metabolism of ETU by FMO2.1 and N413K, respectively, are reasonably similar with the estimates reported in Table 2 . All of the Table S1 ) from GenBank and Ensembl. Sequence coverage included 66 mammalian, two bird, four amphibian, three fish, one insect, five nematode, three plant, two yeast (fungal), and three bacterial FMOs (two that are BVMOs). For the purpose of this article, phenylacetone monooxygenase from T. fusca was treated as an FMO because it is a closely related BVMO and crystals have been obtained (Malito et al., 2004) . The two FMOs that have yielded crystals-yeast FMO from S. pombe (Eswaramoorthy et al., 2006) and bacterial FMO from Methylophaga FMO (Choi et al., 2003; Alfieri et al., 2008) -are included. All the sequences used in the alignment are class B flavoprotein monooxygenases (van Berkel et al., 2006) .
Conserved strand-turn-helix motifs (GxGxxG for FAD and GxGxxG/A for NADP ϩ ) are known to stabilize nucleotide binding. This role was verified by the observed residue interactions from the crystal structure of S. pombe FMO (Eswaramoorthy et al., 2006) . The Ser encoded by residue 195 in human FMO2 is within the NADP ϩ motif (GxGxSG/A) and is highly conserved among FMOs (76 of 89) (Supplemental Fig. S1 ). The only exceptions to this use were that most FMO4s (11 of 13) and Mycobacterium tuberculosis use Thr instead of Ser, whereas primate FMO1 incorporates Pro. It is interesting to note that Ser conservation also extends to the analogous position of the FAD binding motif (GxGxSG), where 87 of 89 proteins incorporate Ser, whereas the remaining two FMOs use Thr and Ala (Supplemental Fig. S1 ).
Extensive conservation of Ser across evolutionary distance implies conservation of a structural role and indicates that examination of Leu substitution in the structural model derived from crystals of Methylophaga sp., S. pombe, or T. fusca could explain the basis for our observation of reduced affinity for NADPH and high loss of enzyme activity when the Leu-containing variant is heated (in the absence of NADPH). Figure 3A visualizes the interactions of Ser213 in the Methylophaga sp. FMO crystal (PDB code 2VQ7) (Alfieri et al., 2008) , the equivalent of Ser195 in human FMO2.1. Ser213 interacts with bacterial Ala191, Tyr212, and Tyr279. Replacement of Ser with Leu213 (Fig. 3B ) would lead to disruption of interactions with all the indicated residues and NADP ϩ , indicating that the effects of S195L substitution are direct and are not simply the result of a shift in an important neighboring residue. The contact residues are also indicated in Supplemental Fig. S1 . The interacting residues are in critical regions. Tyr212 has been singled out for its involvement, together with NADP ϩ , in blocking solvent access to reduced FAD and the catalytic core (Alfieri et al., 2008) . The FMOs of most eukaryotes use Asn instead of Tyr; Tyr212 corresponds to Asn194 of human FMO2.1. Ala191 is in the FMO signature motif FxGxxxHxxxF/Y (at the italicized residue) (Fraaije et al., 2002) and corresponds to residue 173 in human FMO2.1. Human FMO2.1 uses Ser at this site as do the majority (83 of 89 FMOs) of the FMOs examined (Supplemental Fig. S1 ). It is interesting to note that a mutagenesis study performed with cyclohexanone monooxygenase, a BVMO from Acinetobacter sp. NCIB 9871, showed that mutagenesis of the conserved His in the signature motif also resulted in a doubling of the K m for NADPH binding compared with wild-type enzyme (Cheesman et al., 2003) . Methylophaga Tyr279 corresponds to human FMO2.1 Tyr331. This Tyr is the final residue of the prototypic "FATGY" motif; this motif is highly conserved among all the FMOs aligned except for the BVMOs from T. fusca and M. tuberculosis. As reviewed elsewhere , the FATGY motif has also been variously identified as the ATG NADPH motif (E/DxxxxATG) found in flavoproteins with two nucleotide binding domains, and it overlaps two PRINTS motifs known to form a linkage between the NADP ϩ binding domain and active site of relevant proteins. With the number of disruptions predicted by the S195L substitution it is not surprising that we observed altered enzyme performance with this FMO2 variant. The Leu195-Ser173 collisions are expected to distort the structure and thermodynamically destabilize the protein, explaining the greater heat lability of this mutant. NADPH binding to the mutant partly salvages the activity because the favorable interactions with NADPH make the complex have slightly higher stability than the empty mutant enzyme. Stabilization of enzyme activity and structure by cofactor or substrate binding is a common theme. Studies of the BVMO, 4-hydroxyacetophenone monooxygenase, showed that when NADPH was included with 4-hydroxyacetophenone monooxygenase during heat treatment, activity, FAD binding, and quaternary structure were maintained. However, FAD was lost, protein became aggregated, and activity was lost when this protein was heated in the absence of NADPH (van den Heuvel et al., 2005) . Thus, the C4a-hydroperoxy flavin of S195L may not only be subject to solvent attack but also subsequent loss of FAD and aggregation.
The N413K substitution improves enzyme velocity and subsequently calculated specificity constants for the substrates examined but does not fundamentally change the direction of response to treatments such as pH, detergent, and MgCl 2 . Alignment of multiple FMO sequences reveals that this region and site vary in an isoform-specific manner (Supplemental Fig. S1 ). Whereas FMO2s use Asn, FMO1s use Lys and FMO3s and FMO6s generally use Met at the position equivalent to N413K of human FMO2. The analogous Methylophaga FMO site is Arg361 and is on the surface of a monomer far from the active site. Crystallized Methylophaga FMO is a tetramer, and Arg361 is at the interface between two subunits where it interacts directly with one of the other chains near Lys32 (data not shown). In the absence of a crystal structure from a mammalian FMO, it is not clear why N413K enhances enzyme velocity.
It has been suggested that human FMO2 is en route to becoming a pseudogene , but this phenomenon may not be limited to humans. In addition to work describing the occurrence and functional outcomes of the common human FMO2 Q472X nonsense mutation (Dolphin et al., 1998; Whetstine et al., 2000; Krueger et al., 2004) , there is also work describing a common variant FIG. 3 . The consequences of an S195L mutation. A, in the crystal structure of Methylophaga sp. FMO (PDB code 2VQ7), Ser213 (the equivalent of Ser195 in human FMO2) is intimately involved in NADP ϩ binding (short hydrogen bond to atom O2N of the NADP ϩ pyrophosphate and van der Waals contacts with the nicotinamide C␤ atom of Ala191 (equivalent to Ser173 in human FMO2, which has an even larger side chain). B, replacing Ser213 with Leu in the Methylophaga sp. structure leads to major collisions (red disks) with atoms of NADP ϩ and Ala191, explaining why this mutation is highly disruptive to NADP ϩ binding. Analysis done and figure created with PyMOL. of the Norway rat (deletion of two nucleotides results in a frame shift) (Hugonnard et al., 2004) . In the course of assembling additional mammalian FMO2 sequences for alignment, we found an uncharacterized variant in the sole sequence located for Bos taurus (Supplemental Fig. S1 ). Cow FMO2 truncation results from an extended C-terminal deletion. It is not known whether this deletion is fixed or segregating in cows or other closely related species, but this deletion seems to be the third case of a species losing or being in the process of losing functional FMO2. The cow and Norway rat each have a unique truncation position encoding proteins even shorter than human FMO2. Given that human Q472X does not bind FAD (Krueger et al., 2002) , neither cow nor Norway rat FMO2 is expected to generate FAD-bound enzyme. One of the alleles responsible for trimethylaminuria is the human FMO3 variant encoding R492W, an inactive protein that does not bind FAD (Yeung et al., 2007) . Homology modeling with S. pombe FMO places Arg492 in close proximity to its FAD catalytic center, Asn61 (Yeung et al., 2007) . All mammals use Arg at this position, and most eukaryotes retain a positively charged residue (Supplemental Fig. S1 ). It is clear that loss of Arg494, the analogous residue from human FMO2, would be sufficient to prevent FAD binding by Q472X, although other crucial elements may also reside in this region.
Discussion
The studies in this report show that the FMO2 S195L variant expressed on a Gln472 background is less detrimental than we had previously thought , primarily owing to improved enzyme activity when pH is reduced. Our study provides evidence that NADPH, although not capable of forming ideal interactions, nonetheless gives S195L some added stability and preserves some activity. We do not expect that S195L would have the enzymatic stability or activity of wild-type FMO2 under physiological conditions. Evidence of S195L impairment is not limited to thermal sensitivity documented here. We have also observed elevated hydrogen peroxide leakage with the S195L variant compared with FMO2.1 and N413K in reaction mixtures containing NADPH at physiological pH (L. K. Siddens, S. K. Krueger, and D. E. Williams, unpublished studies). Elevated leakage fits the expected shift toward NADPH oxidase activity as a decay product of solvent-exposed C4a-hydroperoxyflavin intermediate when NADPH is weakly bound. NADPHdependent retention of S195L activity to heat and H 2 O 2 leakage data both imply that the reduced flavin is less protected from oxygen in this variant. This leakage is consistent both with destabilization of the structure in the NADPH binding region as indicated by substitution into the crystal structure of Methylophaga and the reduced binding affinity calculated for NADPH from kinetic studies.
Inferences about the role of N413K are necessarily limited because this polymorphism lies in a region that is rich in isoform-specific differences. Presumably N413K is optimized for regeneration of FAD via release of water from FAD-OH and/or release of NADP ϩ , because these are the two slowest steps of the catalytic cycle. Given that FMO1 isoforms use Lys rather than Asn, we would predict a K413N mutation would generate an FMO1 variant with less activity and reduced k cat . Definitive assignment of function will require crystal structure information from a higher organism than is presently available.
Owing to the wide distribution of the FMO2*2 allele, S195L and N413K are expected to yield functional protein only if they are present in combination with the minor FMO2*1 allele in individuals of either African or Hispanic descent. Recent work Veeramah et al., 2008) has shown that in some sub-Saharan African populations FMO2*1 can be present in 26 to 50% of the population, levels previous studies had failed to appreciate owing to lack of information on organ donor origin. Consequently, there are approximately 220 million individuals in sub-Saharan Africa that may express functional protein (Veeramah et al., 2008) . Individuals with SNPs encoding either active N413K (known to exist) or S195L (probably exists) secondary to Gln472 are expected with the highest frequency in these populations.
Codistribution of tuberculosis incidence and FMO2*1 occurrence could have profound implications for the treatment of this prevalent disease. A number of tuberculosis treatments, such as ethionamide and thiacetazone, are prodrug substrates of the M. tuberculosis FMO, EtaA, and are also excellent substrates of human FMO2.1 Francois et al., 2009 ). Metabolism of ethionamide by FMO1, FMO2.1, and FMO3 in vitro alters the GSSG/GSH ratio , suggesting that redox cycling and GSH depletion may result in vivo in an FMO2*1-dependent manner in lung. Further study is warranted because co-occurrence of FMO2.1 and mycobacterial EtaA could affect both the rate of adverse clinical reactions and efficacy of mycobacterial eradication.
Individuals receiving pharmaceutical treatment for genetic disorders caused by nonsense mutations are a new group of individuals that may be expressing functional FMO2 protein. PTC Therapeutics (South Plainfield, NJ) has developed a stop codon read-through drug, PTC124 (Welch et al., 2007) . In theory, PTC124 will produce fulllength protein from all the mRNAs possessing a premature termination codon caused by a nonsense mutation. Thus, treated individuals with the allele for the major FMO2 SNP Q472X could express active FMO2 protein and secondary S195L and N413K SNP-encoding variants. To date, PTC124 has been administered to normal individuals in phase 1 tests and to patients with cystic fibrosis and Duchenne or Becker muscular dystrophy in phase 2 tests. Although the number of individuals receiving this drug now and in the future will probably remain small, the number of diseases tested with this drug regimen is likely to grow. Patients taking PTC124 may develop altered patterns of drug and xenobiotic metabolism as a result of read-through of the Q472X-encoding allele, FMO2*2, and any secondary variants yielding FMO2 with substantial activity. The existence of this subpopulation with newly "acquired" functional FMO2 adds to the necessity that we understand the properties of what are usually secondary mutations, given that they will be uncovered in patients taking this class of drugs.
Strides have been made in understanding the structure and function of mammalian FMO. Channel length and width of substrate binding sites were established with substituted thioureas and phenothiazines, and isoform-dependent differences were identified using substrate probes (Nagata et al., 1990; Guo et al., 1992; Shehin-Johnson et al., 1995; Kim and Ziegler, 2000) . Study of trimethylaminuria-causing gene products marked the earliest efforts to understand naturally occurring human FMO mutations; such studies have confirmed more than 30 rare causative mutations (the 17 documented missense mutations are indicated in Supplemental Table  S1 ), in addition to more common SNPs that may mildly reduce enzyme activity. In some studies, the basis of activity reduction was identified for the expressed protein variants and was attributed to no or reduced FAD cofactor binding, altered K m or k cat , or both. More recently, structural data from crystallized yeast and bacterial FMOs have provided further insight regarding the structural basis of functional FMO3 variants (Eswaramoorthy et al., 2006; Koukouritaki et al., 2007; Yeung et al., 2007; Alfieri et al., 2008) . We expect that these studies will continue to add structure-function knowledge; however, the biggest informational and predictive gains still await successful crystallization of a mammalian FMO. 
